Sunho Biologics Balance Sheet Health
Financial Health criteria checks 5/6
Sunho Biologics has a total shareholder equity of CN¥548.0M and total debt of CN¥23.0M, which brings its debt-to-equity ratio to 4.2%. Its total assets and total liabilities are CN¥587.4M and CN¥39.4M respectively.
Key information
4.2%
Debt to equity ratio
CN¥22.98m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥494.79m |
| Equity | CN¥548.02m |
| Total liabilities | CN¥39.36m |
| Total assets | CN¥587.39m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 2898's short term assets (CN¥514.5M) exceed its short term liabilities (CN¥34.8M).
Long Term Liabilities: 2898's short term assets (CN¥514.5M) exceed its long term liabilities (CN¥4.6M).
Debt to Equity History and Analysis
Debt Level: 2898 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 2898's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2898 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 2898 has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 33.6% each year.